Vor Biopharma (NASDAQ:VOR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Vor Biopharma (NASDAQ:VOR) from a sell rating to a hold rating in a report released on Saturday.

VOR has been the topic of several other research reports. Weiss Ratings upgraded shares of Vor Biopharma from a “sell (d-)” rating to a “sell (d+)” rating in a report on Tuesday, August 11th. Wedbush upped their price target on shares of Vor Biopharma from $18.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, August 12th. Jefferies Financial Group upgraded shares of Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Finally, HC Wainwright restated a “buy” rating and issued a $31.00 price objective on shares of Vor Biopharma in a research note on Monday, May 18th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Vor Biopharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.38.

Vor Biopharma Price Performance

NASDAQ:VOR opened at $23.01 on Friday. Vor Biopharma has a 52 week low of $6.50 and a 52 week high of $50.20. The firm has a 50 day moving average of $18.75 and a 200 day moving average of $16.07.

Vor Biopharma (NASDAQ:VOR) last announced its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11). Equities research analysts anticipate that Vor Biopharma will post -2.7 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in VOR. Goldman Sachs Group Inc. increased its holdings in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after acquiring an additional 58,247 shares in the last quarter. Jane Street Group LLC purchased a new position in Vor Biopharma during the first quarter valued at $140,000. XTX Topco Ltd purchased a new position in Vor Biopharma during the second quarter valued at $66,000. BNP Paribas Financial Markets grew its position in shares of Vor Biopharma by 497.3% in the third quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock valued at $296,000 after purchasing an additional 5,058 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in shares of Vor Biopharma in the third quarter valued at about $230,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).